[RU 486 (mifepristone): from clinical trials to the perspectives for clinical use].
Elia
D
D
Ulmann
A
A
D000019:Abortifacient Agents; D000028:Abortion, Induced; D019049:Developed Countries; D004194:Disease; D004467:Economics; D005060:Europe; D005193:Family Planning Services; D005602:France; D006470:Hemorrhage; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D012098:Reproduction; D012106:Research; D012816:Signs and Symptoms; D013672:Technology
D000019:Abortifacient Agents
Abortifacient Agents--administraction and dosage; Abortion, Drug Induced; Abortion, Induced; Bleeding; Clinical Research; Developed Countries; Diseases; Economic Factors; Europe; Family Planning; Fertility Control, Postconception; France; Mediterranean Countries; Pregnancy; Pregnancy, First Trimester; Reproduction; Research And Development; Research Methodology; Signs And Symptoms; Technology; Western Europe